Cardiovascular & Blood Codexery

Anticoagulant

Substances that prevent or reduce blood coagulation.

Last updated

A chemical agent that slows or stops blood from clotting, thereby extending the time it takes for coagulation to occur, is termed an anticoagulant.[1] In blood-feeding creatures such as leeches and mosquitoes, naturally occurring anticoagulants are present that prevent the area of the bite from clotting.[1] Warfarin and heparin are two examples of frequently used anticoagulants.[2]

Quick Facts

Type
Chemical substance and medication class
Common examples
Warfarin and heparin
Major risk
Increased risk of bleeding
Forms
Oral (pills or tablets) and intravenous

Facts from the source article.

Key facts and history

DOACs were previously called novel oral anticoagulants (NOACs).[3] The initial approval for warfarin, which is among the earliest anticoagulants, was as a poison for rodents.[4] Within a large medical practice seeing patients with many different conditions, the anticoagulant warfarin was the one most often prescribed.[5][6] The year 2008 and the period following it marked the introduction of direct oral anticoagulants (DOACs).[3]

Compared to coumarins, DOACs have demonstrated equivalent or superior effectiveness while causing fewer severe adverse effects.[7] An elevated chance of bleeding constitutes the most significant danger associated with anticoagulation therapy.[8] For warfarin, the yearly occurrence of bleeding is estimated to be between 15 and 20 percent.[9] The FDA has given its approval for the use of idarucizumab, a reversal agent for dabigatran.[10]

What the research sources say

A 2016 study found that warfarin remained the dominant anticoagulant prescribed for patients with atrial fibrillation and venous thromboembolism in a large ambulatory practice.[5] In that study, 76% of patients with only atrial fibrillation were prescribed warfarin, compared with 24% prescribed a novel anticoagulant.[5] Direct oral anticoagulants are first-line agents for eligible patients for treating venous thromboembolism and preventing stroke in those with nonvalvular atrial fibrillation.[11] Low-molecular-weight heparin continues to be recommended as a first-line treatment for patients with venous thromboembolism and active cancer.[11]

Idarucizumab has been effective for reversing the anticoagulant effects of dabigatran, and andexanet alfa has been effective for reversing the effects of rivaroxaban and apixaban.[11]

References

  1. Wikipedia, "Anticoagulant" (CC BY-SA 4.0), which cites: "Overview: Anticoagulant medicines", Health A to Z, 26 July 2021; "Chemical and mechanical alternatives to leech therapy: a systematic review and critical appraisal", Journal of Reconstructive Microsurgery, October 2011, p. 481–86; "Detection of heparin in the salivary gland and midgut of Aedes togoi", The Korean Journal of Parasitology, April 2014, p. 183–88 (we also read that source) en.wikipedia.org
  2. Wikipedia, "Anticoagulant" (CC BY-SA 4.0), which cites: Winslow, "Race Is on for the Next Blood Thinner", The Wall Street Journal, 2007-12-10, p. A12 (original not read by us) en.wikipedia.org
  3. Wikipedia, "Anticoagulant" (CC BY-SA 4.0), which cites: "Human medicines European public assessment report (EPAR): Pradaxa, dabigatran etexilate, Arthroplasty, Replacement, Venous Thromboembolism, Date of authorisation: 17/03/2008, Revision: 29, Status: Authorised", Case Medi; Almarshad, "Use of direct oral anticoagulants in daily practice", American Journal of Blood Research, December 2018, p. 57–72; Verdecchia, "Why switch from warfarin to NOACs?", Internal and Emergency Medicine, April 2016, p. 289–93; Diener, "Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke en.wikipedia.org
  4. Wikipedia, "Anticoagulant" (CC BY-SA 4.0), which cites: "Anticoagulant treatment for subsegmental pulmonary embolism", The Cochrane Database of Systematic Reviews, 7 February 2020; "Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis", ; "Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses", Clinical Therapeutics, July 201 en.wikipedia.org
  5. "Prescribing Patterns of Novel Anticoagulants Within a Statewide Multispecialty Practice", American Journal of Pharmacy Benefits, Jun 21, 2016, p. 97–102. facts only, no text reused. pharmacytimes.com
  6. Wikipedia, "Anticoagulant" (CC BY-SA 4.0), which cites: "Prescribing Patterns of Novel Anticoagulants Within a Statewide Multispecialty Practice", American Journal of Pharmacy Benefits, Jun 21, 2016, p. 97–102; Patel, "Warfarin", StatPearls, 2026; "Bridging Anticoagulation", Circulation, 2012, p. e496-8; Patel, "Warfarin", StatPearls, 2026; Wigle, "Anticoagulation: Updated Guidelines for Outpatient Management", American Family Physician, 2019-10-01, p. 426–434; Schaefer, "Drugs During Pregnancy and Lactation (Second Edition)", Academic Press, 2007-01-01, p. 695–698 (we also read that source) en.wikipedia.org
  7. Wikipedia, "Anticoagulant" (CC BY-SA 4.0), which cites: "Anticoagulation in atrial fibrillation: NOAC's the word", Deutsches Ärzteblatt International, August 2013, p. 523–4; Heine, "Orale Antikoagulation bei chronischer Nierenerkrankung und Vorhofflimmern", Deutsches Ärzteblatt Online, 2018-04-27, p. 287–94 (original not read by us) en.wikipedia.org
  8. Wikipedia, "Anticoagulant" (CC BY-SA 4.0), which cites: "An Update on the "Novel" and Direct Oral Anticoagulants, and Long-Term Anticoagulant Therapy", Clinics in Chest Medicine, September 2018, p. 583–93; "Scoring Systems for Estimating the Risk of Anticoagulant-Associated Bleeding", Seminars in Thrombosis and Hemostasis, July 2017, p. 514–24; "The hemorrhage risk of prophylactic external ventricular drain insertion in aneurysmal subarachnoid hemorrhage patients requiring endovascular aneurysm treatment: a systematic review and meta-analysis", Journal of Neuro; "Meta-Analysis of Usefulness of en.wikipedia.org
  9. Wikipedia, "Anticoagulant" (CC BY-SA 4.0), which cites: "Reversal of warfarin-induced hemorrhage in the emergency department", The Western Journal of Emergency Medicine, November 2011, p. 386–92; "Breadth of complications of long-term oral anticoagulant care", Hematology. American Society of Hematology. Education Program, November 2018, p. 432–38; "Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study", The Lancet. Haematolo; "Major hemorrhage and tolera en.wikipedia.org
  10. Wikipedia, "Anticoagulant" (CC BY-SA 4.0), which cites: Ozaki, "Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis", Circulation: Cardiovascular Quality and Outcomes, 2020 (original not read by us) en.wikipedia.org
  11. Wigle, "Anticoagulation: Updated Guidelines for Outpatient Management", American Family Physician, 2019-10-01, p. 426–434. facts only, no text reused. aafp.org

Each numbered sentence above was checked against the source it cites before publication. Sentences citing Wikipedia adapt text from the English Wikipedia article Anticoagulant (contributors), used under CC BY-SA 4.0; this entry is available under the same licence. Other sources were used for facts only; no text or images are copied from them.

More in Cardiovascular & Blood

Sources

Compiled from Wikipedia and the sources listed below. Text from Wikipedia is available under CC BY-SA 4.0; this entry is adapted from it.

Spotted an error? Know more?

Reader corrections go straight into our review queue. Suggest an edit · How this site is sourced

Comments

Loading…
Open in the interactive codex →